Yang, M., Zheng, C., Miao, Y., Yin, C., Tang, L., Zhang, C., Yu, P., Han, Q., Ma, Y., Li, S., Jiang, G., Li, W., Xia, P.

BTLA promoter hypomethylation correlates with enhanced immune cell infiltration, favorable prognosis, and immunotherapy response in melanoma

13 de March de 2025 by Yang, M., Zheng, C., Miao, Y., Yin, C., Tang, L., Zhang, C., Yu, P., Han, Q., Ma, Y., Li, S., Jiang, G., Li, W., Xia, P.

Background
Immune checkpoint blockade (ICB)-based immunotherapy has significantly improved survival in advanced melanoma. However, many patients exhibit resistance to these therapies. This study examines the impact of BTLA promoter methylation on its …